Therapeutic Goods Order No. 94 (Standard for Haematopoietic Progenitor Cells derived from Cord Blood) 2017
This Therapeutic Goods Order constitutes a standard in relation to therapeutic goods that are haematopoietic progenitor cells derived from cord blood.
Official version of legislation
The Federal Register of Legislation is the authorised Australian Government website for Commonwealth legislation. It contains the full text and details of the life cycle of individual laws.
Guidance referring to this legislation
-
GuidanceThis guidance explains how sponsors and manufacturers should prepare and maintain a Technical Master File (TMF) for blood, blood components, and haematopoietic progenitor cells. It outlines TMF requirements, submission processes, evaluation pathways and change management requirements.
-
GuidanceGuidance for manufacturers and sponsors on the product standards that apply to haematopoietic progenitor cells (HPCs).
Product types